Agenus Inc. Common Stock (AGEN)

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also d…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

81

Website

agenusbio.com/

Fundamentals

1-day range

$7.61$8.07

Market cap

$335.19M

P/E (trailing)

4.88

P/E (forward)

-127.67

EPS (trailing)

$1.67

Dividend yield

—

Beta

1.39

Avg. volume

4.25M

Forecasts

2 analyst ratings

Agenus Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AGEN

  Agenus Inc. Common Stock

  $7.67

  ▼ 1.79%
  Market cap $335.19MP/E 4.88
  $2.71$8.85
• IPSC

  Century Therapeutics Inc. Common Stock

  $2.03

  ▼ 9.19%
  Market cap $342.67MP/E —
  $0.435$3.04
• IKT

  Inhibikase Therapeutics Inc. Common Stock

  $2.42

  ▼ 2.23%
  Market cap $318.20MP/E —
  $1.33$2.53
• LXEO

  Lexeo Therapeutics Inc. Common Stock

  $4.87

  ▼ 2.51%
  Market cap $357.27MP/E —
• PALI

  Palisade Bio Inc. Common Stock

  $2.01

  ▼ 4.74%
  Market cap $362.78MP/E 3.25
  $0.53$2.86
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $303.96MP/E —
  $2.26$10.4
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Agenus Says Published Phase 1b Data Showed 21.2-Month Median Overall Survival, 33% Three-Year Overall Survival And 21% Objective Response Rate With Botensilimab Plus Balstilimab In 123 Pretreated MSS Colorectal Cancer Patients
  benzinga · 8/28/2026
• Agenus (NASDAQ:AGEN) Passes Minervini Trend Template with High Growth Momentum
  ChartMill · 8/27/2026
• Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response
  Benzinga · 8/26/2026
• 10 Health Care Stocks Whale Activity In Today’s Session
  Benzinga · 8/21/2026
• Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
  Benzinga · 8/20/2026
• HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
  Benzinga · 8/11/2026
• Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
  Benzinga · 8/7/2026
• Agenus Q2 Sales $34.500M Beat $34.000M Estimate
  Benzinga · 8/6/2026

• Garo H. Armen · August 10, 2026 · Grant

  1.97M
• Thomas L. Harrison · August 5, 2026 · Grant

  50.0K
• Brian Corvese · August 5, 2026 · Grant

  100.0K
• Wright Timothy · August 5, 2026 · Grant

  50.0K
• O'Day Steven J · August 5, 2026 · Grant

  100.0K
• Susan B. Hirsch · August 5, 2026 · Grant

  50.0K
• Jennifer Buell · August 5, 2026 · Grant

  200.0K
• Garo H. Armen · July 10, 2026 · Grant

  4.9K @ $3.35
• Thomas L. Harrison · July 1, 2026 · Grant

  8.5K @ $3.58
• Wright Timothy · July 1, 2026 · Grant

  2.3K
• Garo H. Armen · June 12, 2026 · Grant

  4.9K @ $3.3
• Garo H. Armen · May 29, 2026 · Grant

  4.6K @ $3.5
• Garo H. Armen · May 15, 2026 · Grant

  4.5K @ $3.58
• Garo H. Armen · May 1, 2026 · Grant

  4.2K @ $3.84
• Susan B. Hirsch · April 24, 2026 · Grant

  105.0K

Institutional Ownership

March 31, 2026

Total shares held

7.95M

Total value held

$25.76M

Institutional holders

83